*November 2020* This new clinical trial is for those people whose EGFR lung cancer has transformed to small cell lung cancer.This trial covers travel expenses as well. Any questions can be directed to Dr. Anish Thomas at: Anish.Thomas@nci.gov. (In
*November 2020* Neratinib (Nerlynx) showcased early activity when used in patients with metastatic non–small cell lung cancer (NSCLC) who harbor EGFR exon 18 mutations, according to interim data from the phase 2 SUMMIT trial.1 Results demonstrated that among 10 evaluable patients
*November 2020* In the treatment of lung tumors, alterations in MET as well as gene fusions in RET and NTRK are now established actionable drivers of oncogenesis, made evident by the availability of FDA-approved and guidelines-indicated therapies for each
*October 2020* Bone pain in patients with cancer is commonly caused by cancer cells that have spread to the bones, called bone metastases. Bone pain is commonly the first symptom of bone metastases and may lead to tests that
*November 2020* Alexander Spira, MD, PhD, a medical oncologist and director of the Virginia Cancer Specialists Research Institute and the Phase 1 Trial Program, discusses the phase 1 CHRYSALIS trial of amivantamab (JNJ-61186372) plus lazertinib (YH25448) in 2 EGFR-mutant
*November 2020* Targeted treatments for non-small cell lung cancer: recent progress and future challenges. Some of the most common driving mutations for NSCLC occur in EGFR, the gene that encodes for the protein epidermal growth factor receptor. These EGFR mutations can be
*November 2020* Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene addicted tumor. In these patients, despite the clear benefits
*November 2020* MET mutations can be a resistance mechanism to TKI treatment (Tarceva, Tagrisso, etc.) Roman Perez-Soler, MD, professor in the Department of Medicine (Oncology) and Department of Molecular Pharmacology, and chief of the Department of Medicine Division of
*November 2020* The role of targeted therapy is rapidly expanding in the treatment paradigm of patients with non–small cell lung cancer (NSCLC), said D. Ross Camidge, MD, PhD, who added that among multiple therapeutic options for common aberrations, such
*November 2020* Communities sharing particular types of the disease are helping steer research towards better therapies. Patient advocates often want immediate results but this can be at odds with the slow pace of scientific investigation. Yet clinicians and scientists
*September 2020* New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc., finds that the novel SHP2 inhibitor IACS-13909 is able to overcome multiple therapeutic-resistance mechanisms in non-small cell
*October 2020* Shirish M. Gadgeel, MD, MBBS, highlights some of the recent targeted therapy advances in NSCLC and how ongoing research is taking the paradigm to the next level. The molecular landscape of non–small cell lung cancer (NSCLC), especially
*October 2020* Identifying how to best treat patients who develop resistance to EGFR-targeted therapy, especially frontline osimertinib (Tagrisso), is part of the next chapter of research in this molecularly driven non–small cell lung cancer (NSCLC) arena, explained Christina Baik, MD,
*October 2020* The GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series. Dr. Jack West has a virtual discussion with Helena A. Yu, MD, medical oncologist with Memorial Sloan Kettering specializing in Lung Cancer and Targeted Therapies
*October 2020* — Similar survival and less cognitive decline compared with conventional WBRT Stereotactic radiosurgery (SRS) for cancer patients with four to 15 brain metastases staved off cognitive decline better than conventional whole-brain radiation therapy (WBRT), while yielding similar
*September 2020* Note: this is in context of HER2, another resistance mechanism of EGFR TKIs. Trastuzumab deruxtecan has demonstrated impressive clinical activity with modest myelosuppression and toxicities in patients with pretreated NSCLC, says Rizvi. According to data from the phase
*September 2020* The first targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) harboring MET mutations, capmatinib (Tabrecta), has shown deep and durable responses, conclude investigators of the pivotal trial that led to the drug's approval. Responses
*September 2020* A small-molecule inhibitor targeting a KRAS mutation achieved a high rate of disease control in a preliminary study of patients with non-small cell lung cancer (NSCLC). A third of patients with NSCLC had objective responses with sotorasib, and 88.1%
*September 2020* Additionally, the findings showed that BLU-945 potently and selectively inhibited triple-mutant EGFR, harboring the most common on-target resistance mutations to standard EGFR-targeted therapies, including the third-generation EGFR TKI osimertinib (Tagrisso). Specifically, BLU-945 inhibited triple-mutant EGFR with sub-nanomolar
*September 2020* The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone. Read more.
*September 2020* The combination of amivantamab (JNJ-61186372; JNJ-6372) and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib (Tagrisso)-resistant patients with advanced EGFR-mutant non–small cell lung cancer (NSCLC), according to findings from the phase 1
*September 2020* Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival. Read more.
*September 2020* Nathan A. Pennell, MD, PhD, an associate professor in the Department of Medicine and director of the Lung Cancer Medical Oncology Program at the Taussig Cancer Institute of Cleveland Clinic, discusses the evolution of targeting HER2 in lung cancer. Watch the video.
*August 2020* The FDA has granted a priority review designation to new drug application (NDA) for tepotinib as a treatment for patient with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor a MET exon 14 (METex14) skipping mutation identified via
*August 2020* The FDA has granted Priority Review to the New Drug Application (NDA) for trilaciclib (G1T28) for the treatment of patients with small cell lung cancer (SCLC) who are receiving chemotherapy, G1 Therapeutics announced in a press release.
*August 2020* Dr. Levy discusses the challenges of targeting KRAS and highlighted some of the investigational agents directed toward KRAS G12C mutations that have emerged in the NSCLC pipeline. For the past 30 years, KRAS was believed to be an undruggable
*August 2020* Joshua Palmer, MD, discusses a pooled analysis of 2 randomized clinical trials that compared how clinical outcomes and quality of life were impacted with stereotactic radiosurgery versus whole-brain radiation therapy in patients with brain metastases. Watch video here.
*August 2020* "Brain metastases harbor distinct clinically actionable genetic alterations compared to their primary tumors and extracranial sites." The use of targeted therapies directed at genetic alterations specific to brain metastases is emerging as a viable precision medicine approach
*September 2020* What are new treatment options for EGFR lung cancer patients? In this segment from our recent Lung Cancer Answers Now program, two lung cancer experts, Dr. Bruce Johnson from Dana-Farber Cancer Institute and Dr. Alex Spira from
*August 2020* Research into mutations in the gene encoding the epidermal growth factor receptor (EGFR) protein has revolutionized non–small cell lung cancer (NSCLC) treatment in recent years, yet the science supporting targeting of this oncogene is still being elucidated.
*July 2020* Leptomeningeal metastasis (LM) is a devastating, late-stage complication of various solid tumors and is characterized by the diffuse dissemination of malignant tumor cells into the cerebrospinal fluid (CSF) and leptomeninges. Metastasis to this fluid-filled space can quickly spread
*July 2020* While individualized oncologic treatments are becoming a common practice, it is necessary to evaluate brain metastases (BM) management in a homogeneous primitive population. In patients with a limited number of BM from NSCLC, SRT is an effective
*July 2020* In an interview with Targeted Oncology, Balazs Halmos, MD, MS, director of the Multidisciplinary Thoracic Oncology Program and director of the Section of Thoracic Medical Oncology for Montefiore Health Systems, and first director of Clinical Cancer Genetics and professor
*June 2020* The FDA had granted accelerated approval to the anti-cancer agent lurbinectedin (Zepzelca) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) whose disease has progressed on or after platinum-based chemotherapy. The accelerated approval
*June 2020* Note: Capmatinib was approved by the FDA in May 2020 for MET exon 14 skipping mutation. The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved capmatinib (Tabrecta; formerly INC280) for patients with MET exon 14 skipping (METex14) mutation–positive advanced and/or
*June 2020* Patients with small cell lung cancer (SCLC) with brain metastases saw similar if not slightly better survival when treated with stereotactic radiosurgery (SRS) compared with standard-of-care whole brain radiotherapy (WBRT), findings from the FIRE-SCLC study indicated. Read more.
*July 2020* In the trial, 49 patients enrolled between August 2016 and May 2018 at Memorial Sloan Kettering Cancer Center received osimertinib at 80 mg daily and bevacizumab at 15 mg/kg once every 3 weeks, the maximum-tolerated dose identified
*May 2020* The first lung cancer patient to be treated with a new type of immunotherapy involving the re-engineering of a patient's T cells, known as TCR T-cell therapy, took place at Winship Cancer Institute of Emory University (Winship)
*May 2020* The study results indicated clinical efficacy against central nervous system metastases in a cohort of patients. Almonertinib also displayed an overall favorable safety profile. Clinical benefit was observed with almonertinib (HS-10296) as treatment of patients with EGFR T790M-mutant non–small
*June 2020* Webcast: Join the EGFR Registers and top lung cancer specialists discuss facts vs myths in lung cancer treatment. A must-see for EGFR lung cancer patients/survivors. Register and watch it here.
*June 2020* Webcast: Listen to top experts in lung cancer discuss and interpret the latest research from ASCO 2020 with EGFR Resisters co-founders, Ivy Elkins and Jill Feldman. Very informative and a must-watch for lung cancer survivors. Register and
*March 2020* A biopsy sample of tissue often is tested for specific genetic variations (also referred to as mutations) that may have a targeted inhibitor that represents a clear optimal treatment for that cancer. However, it may not be possible
*March 2020* Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to
*March 2020* Targeted sequencing of patients with acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) for EGFR T790M-mutant non-small cell lung cancer (NSCLC) revealed that resistance is associated with diverse pathways. The retrospective study looked at the genomic
*February 2020* Ravi Salgia, MD, PhD, is the Arthur & Rosalie Kaplan Endowed Chair in Medical Oncology and the associate director for clinical sciences at City of Hope’s Comprehensive Cancer Center. His many decades of research in MET and
*March 2020* The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for JNJ-6372 to Janssen Pharmaceutical, a Johnson & Johnson Company. NJ-6372 is an investigational treatment for metastatic non-small cell lung cancer (mNSCLC) with epidermal growth
*March 2020* Osimertinib (Tagrisso) is the standard frontline therapy for patients with metastatic, EGFR-mutant non–small cell lung cancer (NSCLC), and although the drug can provide years of benefit, more options beyond chemotherapy are needed for those who progress on this
*January 2020* Among 62 patients who met eligibility critieria, histologic transformation, primarily squamous transformation, was identified in 15% of first-line osimertinib cases and 14% of later-line cases. Nineteen percent (5/27) of patients treated with first-line osimertinib had off-target genetic
*February 2020* Positive news for METex14 mutated NSCLC patients. Note this is also good news for patients with EGFR-Independent acquired resistance after osimertinib. (Mesenchymal epithelial transition (MET) amplification is a common mechanism of resistance to EGFR-TKI treatment, bserved in
*January 2020* Researchers in the Center for Cancer Research have found that circulating lymphocytes can be stimulated in the laboratory to generate cells that can recognize TP53 gene mutations. Mutations to the TP53 gene are found in about 40
*December 2019* Checkpoint inhibitors come with a huge caveat: They only help a small subset of patients. Doctors struggle to predict who these patients are and—just as important—who they aren't. Results from a new study published Dec. 19 in
*January 2020* Oncoprex in combination with osimertinib (Tagrisso) received fast track designation from the FDA to treat patients with non-small cell lung cancer (NSCLC) with EFGR mutations that progressed after treatment with osimertinib alone, according to Genprex, Inc., the immunogene therapy’s
*January 2020* The FDA has scheduled an Oncologic Drugs Advisory Committee (ODAC) hearing for February 26, 2020, to discuss data supporting a supplemental biologics license application (sBLA) for intravenous ramucirumab (Cyramza) injection for use in combination with erlotinib (Tarceva)
*January 2020* Dana-Farber’s Pasi Jänne, MD, PhD, and his colleagues say they have discovered a mechanism within lung cancer cells that enables the cells to lie dormant and avoid destruction by the cancer drugs. Read more.
*December 2019* With the inevitability of resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with EGFR-mutant non–small cell lung cancer (NSCLC), novel options like lazertinib (YH25448), an irreversible, third-generation, mutant-selective, EGFR TKI are being explored. Lazertinib
*December 2019* SEONGNAM, South Korea, Dec. 19, 2019 /PRNewswire/ -- Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company filed an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) and the
*December 2019* Adding chemotherapy to a targeted agent doubled progression-free survival (PFS) for patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), according to two randomized trials. A phase III trial from India showed that median PFS increased from 8 months
*December 2019* Patients with EGFR-mutant (m) non-small-cell lung cancer (NSCLC) and leptomeningeal metastases (LM) respond favorably to high daily doses of osimertinib, phase 1 BLOOM study data suggest. Myung-Ju Ahn (Sungkyunkwan University School of Medicine, Seoul, Republic of Korea) and
*January 2020* Dana-Farber Cancer Institute will create the Chen-Huang Center for EGFR (epidermal growth factor receptor) Mutant Lung Cancers to stimulate research, promote clinical trials, and strengthen the Institute’s capabilities for studying and treating lung cancer. The Chen-Huang Center
*December 2019* Project PRIORITY (Patient Reported Initiative On Resistance, Incidence, Treatment studY), is a collaboration between LUNGevity Foundation and the EGFR Resisters—a grassroots, patient-driven community dedicated exclusively to changing EGFR-positive lung cancer into a manageable chronic disease. Goal of Project
*November 2019* Phase II progression on any TKI with a new 3rd generation TKI, lazertinib. Location: Montefiore/Einstein in NYC. More information. The JNJ-372 (or JJNJ-61186372) was recently updated with the addition of Lazertinib as one of its arms to
*October 2019* Presented by EGFR Resisters Co-Founders. * Hospitalization - While TKIs are superior to other treatments for EGFR positive lung cancer patients, there is still a large number that experience severe side effects that require urgent medical care and/or
*September 2019* by Dr. Mark Kris for Medscape This is Mark Kris from Memorial Sloan Kettering. Just when we thought we were all set with EGFR, suddenly we have some disruptive information that challenges how we're going to treat
*June 2019* by Nichole Tucker for Targeted Oncology Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) have made a well-documented impact on outcomes for patients with non–small cell lung cancer (NSCLC) who harbor EGFR mutations; the challenge is
*October 2019* by Caroline Seymour for OncLive Insight into the natural history of EGFR-, ALK-, and ROS1-positive non–small cell lung cancer (NSCLC) has led to the development of novel targeted treatments in the frontline setting as well as expanding
*October 2018* by Shalmali Pal Medpage Today and ASCO Chimeric antigen receptor (CAR) T-cell therapy took a victory lap in early 2018 when it was named the "Advance of the Year" in the ASCO Annual Report. Versions of CAR-T cell
*August 2019* Science Immunology Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are a first-line therapy for rapidly killing tumors such as those associated with non–small cell lung cancer by blocking oncogenic receptor signaling, but tumor relapse often
*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. Tagrissio, Tarceva and other TKI therapy for EGFR + NSCLC continue to evolve and improve survival.Advances in cancer research have highlighted the importance of understanding the specific characteristics of each person’s cancer. These
*July 2019* by Dr. C.H. Weaver M.D. for CancerConnect. BiTE antibodies are showing promise as a potential new treatment option for those of us that have progressed on standard of care treatment. What exactly is a BiTE antibody? BiTE is short
*July 2019* The Oncologist. With the advent of immunotherapy, substantial progress has been made in improving outcomes for patients with advanced cancer. However, not all patients benefit equally from treatment, and confounding immune‐related issues may have an impact. Several
Understand the EGFR mutation in lung cancer through this discussion between Dr. Natasha Leighl of Princess Margaret Hospital in Toronto and patient and advocate Jill Feldmen. LCFA's Hope with Answers' Intro video series provides basic information for those newly
We are very excited to announce that the EGFR Resisters will be holding our first Research Summit in collaboration with CEC Oncology, thanks to an independent educational grant from AstraZeneca. We are currently inviting Young Investigators (Junior Faculty or
*June 2019* written by Ivy Elkins for Lungcancer.net I just saw my 18-year-old son graduate from high school. Although this seemed impossible when I was first diagnosed in 2013, I was here to watch him walk across the stage
*June 2019* Medscape. The latest research indicates immunotherapy followed by osimertinib resulted in serious irAEs (severe immune related adverse events) in some advanced lung cancer patients. Medscape (3/20, Castellino, Subscription Publication) reports a study team “notes that serious iirAEs were
*January 2019* Lung Cancer. This small study from Taiwan was performed to investigate the relationship between PD-L1 expression levels and resistance to EGFR-TKI medications in patients with treatment-naïve advanced EGFR mutant lung adenocarcinoma. (By treatment naïve, these patients had
*March 2019* Overview written by Donald Ox. This article deals with a case study of the latest clinical data of brigatinib + cetuximab combo that has stabilized a triple-mutant EGFR patient with concomitant EGFR-T790M and C797S mutations. Brigatinib, the
*March 2019* This is an overview (written by Donald Ox) of the current EGFR TKIs and acquired resistance leading to the effectiveness of the afatinib + cetuximab combo treatment especially useful for T790M negative patients who developed acquired resistance to
*March 2019* Currently available for research purposes only, the Signatera (RUO) is the first ctDNA (circulating tumor DNA) assay custom-built for treatment monitoring and minimal residual disease (MRD) assessment. The test is being developed by Natera and is not yet
*January 29, 2019* Lungevity, by Juhi Kunde. In 2004, after the discovery of mutations in the EGFR gene in lung cancer, the FDA approved a targeted therapy that increased survival in EGFR-positive NSCLC patients. However, the tumors inevitably became
*January 2019* Harvard Health Publishing, Harvard Medical School, by Stephen Lyons. When Dr. Lecia Sequist was undergoing her training to become a medical oncologist at Massachusetts General Hospital (MGH) in the early 2000s, the treatments available for lung cancer
*January 25, 2019* Targeted Oncology, Tony Berberabe. Patients who continued receiving osimertinib (Tagrisso) after their non–small cell lung cancer (NSCLC) had progressed demonstrated a prolonged benefit beyond the initial progression event, according to a retrospective analysis of 118 patients from
*November 10, 2018* GRACE partnered with Swedish Cancer Institute to present a discussion on Local Therapies for Metastatic Lung Cancer. Videos from the live webcast: Newer Technologies in Radiation; Novel Indications for Local Therapy in Advanced NSCLC; Systemic Therapies
*December 10, 2018, University of Texas M. D. Anderson Cancer Center* Researchers at The University of Texas MD Anderson Cancer Center have identified a link between an enzyme tied to cancer formation and therapy resistance in patients with epidermal growth
June 12 2018. A first of its kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer (NSCLC), under a collaboration agreement between Cancer Research UK and Asterias Biotherapeutics Inc. Cancer
Scientists, physicians and patients collaborate to improve treatment for rare cancer SAN CARLOS, CA (November 14, 2018) — The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology and EGFR Resisters today announced the launch of a new study to create a novel bank of patient derived
*NATURE COMMUNICATIONS | (2018) 9:4655 | DOI: 10.1038/s41467-018-07078-0 | www.nature.com/naturecommunications * The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. In a subgroup of these patients we identified an association between
*November 7, 2018* Janssen Biotech has bought Yuhan’s Lazertinib, a novel clinical-stage therapeutic candidate for the treatment of patients with non-small cell lung cancer (NSCLC). J&J’s pharma arm, Janssen, struck the deal with South Korea-based Yuhan and has agreed
By Donna Fernandez · November 9, 2018. I generally begin November by listing, day by day, that for which I am grateful. Some days, the only thing that really strikes me is that I got up that morning or that the sun is shining.
June 19th Living Room "Resistance to Targeted Therapy" Dr. Colin Blakely will be discussing all the questions about progression in your lung cancer and where to go and what to do. Dr. Blakely will be talking about what is happening in the
*** This article was first posted on www.curetoday.com*** During summer 2015, Teri Kennedy was at a yoga festival in Squaw Valley, California, when she started to wheeze and had trouble breathing. The inhaler her doctor gave her didn’t help.
Do you (or a loved one) have EGFR-positive lung cancer? Your voice matters! By participating in this survey, YOU could help shape EGFR-positive lung cancer treatment development and future research, ensuring that they address what is most important to the EGFR-positive lung cancer community.